Regeneron, Intellia to develop CRISPR/Cas9-based treatments

By The Science Advisory Board staff writers

June 1, 2020 -- Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their existing collaboration to provide Regeneron with rights to develop in vivo CRISPR/Cas9-based therapeutic targets and for the two firms together to develop treatments for hemophilia A and B.

Under terms of the deal, Regeneron will pay Intellia $70 million up front and make an additional investment in the firm of $30 million in the near future. The new agreement expands the companies' collaboration through April 2024. In preclinical studies, the companies demonstrated a CRISPR/Cas9-mediated targeted transgene insertion in the liver of nonhuman primates, which generated normal or higher levels of circulating human factor IX.

Regeneron will have rights to discover and develop CRISPR/Cas9-based therapeutic products for an additional five in vivo liver targets, for a total of up to 15 targets. Regeneron will also receive a royalty-bearing, nonexclusive license to certain Intellia intellectual property to develop and commercialize up to 10 ex vivo CRISPR/Cas9 products in defined cell types.

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage...
Regeneron inks human genetics research collaboration
Regeneron Pharmaceuticals has established a human genetics research collaboration with the Colorado Center for Personalized Medicine at the University...
Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.
MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second...
CRISPR - A New Era in Genome Editing
A major buzzword in the science world recently has been CRISPR: short for Clustered Regularly Interspaced Short Palindromic Repeats. This is a simple,...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter